• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Iron Metabolism and Brain Development in Premature Infants
Yafeng Wang1,2,3, Yanan Wu2, Tao Li1,2,3, Xiaoyang Wang2,4 and Changlian Zhu2,3* 1Department of Neonatology (NICU), Children’s Hospital Affiliated Zhengzhou University, Zhengzhou, China 2Henan Key Laboratory of Child Brain Injury, Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China 3Department of Clinical Neuroscience, Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden 4Department of Physiology, Sahlgrenska Academy, Institute of Neuroscience and Physiology, University of Got...
Source: Frontiers in Physiology - April 24, 2019 Category: Physiology Source Type: research

The lncRNA MALAT1 rs619586 G Variant Confers Decreased Susceptibility to Recurrent Miscarriage
In conclusion, our study suggests that the rs619586 G variant may have potential protective effects conferring a decreased risk of recurrent miscarriage in the southern Chinese population. Introduction Recurrent miscarriage is defined as the loss of two or more consecutive pregnancies before 20 weeks of gestation (Jaslow et al., 2010; Diejomaoh, 2015). The occurrence of recurrent miscarriage is associated with many factors, including genetic factors, immunological dysfunction, endocrine disorders, unhealthy lifestyles and defects of the reproductive organs (Saravelos and Regan, 2014; Sen et al., 2014; Garrido-Gimen...
Source: Frontiers in Physiology - April 8, 2019 Category: Physiology Source Type: research

Restrictive Versus Liberal Red Blood Cell Transfusion for Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Conclusion:This meta-analysis showed that restrictive strategies for RBC transfusion are as safe as liberal strategies in patients undergoing cardiac surgery.Key points:Restrictive strategies for red blood cell transfusion are as safe as liberal approaches in patients undergoing cardiac surgery.Longer duration of stay in the intensive care unit is more common in patients managed with a restrictive transfusion approach. However, the overall hospital length of stay appeared to be similar between both groups.Further studies are needed to ascertain threshold triggers for RBC transfusion.Figure.DisclosuresHassan: abott: Other: ...
Source: Blood - November 21, 2018 Category: Hematology Authors: Kheiri, B., Abdalla, A., Osman, M., Haykal, T., Chintalapati, S., Cranford, J., Ahmed, S., Hassan, M., Bachuwa, G., Bhatt, D. L. Tags: 401. Basic Science and Clinical Practice in Blood Transfusion: Poster III Source Type: research

Ischemic Stroke Related to Severe Iron-Deficiency Anemia in Adults May Benefit from Blood Transfusion (P01.232)
CONCLUSIONS: Prevalence of IDA is 1-20%; it is 3.9% in our AIS population and is often related to untreated uterine bleeding. As described in the pediatric population, severe IDA may be an underlying mechanism of ischemic stroke in adults, therefore, efforts must be undertaken to identify and treat the cause of the anemia. While patients with AIS and severe IDA may receive TPA, blood transfusion may be considered as an adjuvant therapy.Supported by: SPOTRIAS P50 NS044227 & NIH Training Grant 5T 32NS0077412-12.Disclosure: Dr. Choi has nothing to disclose. Dr. Sanchez-Rotunno has nothing to disclose. Dr. Gonzales has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Choi, E., Sanchez-Rotunno, M., Gonzales, N. Tags: P01 Cerebrovascular Disease I Source Type: research